Common name CBA/CaH
Coat colour Agouti (A/A)
Location Area Oz2
MHC haplotype: H2K
k Complement Factor: C5 normal
CBA/CaH for its low activity and docile behaviour.
This strain has high overall tumour incidence, which includes hepatomas and mammary tumours. Often used in cancer research to study tumorigenesis and tumour progression.
CBA/CaH mice are resistant to the induction of atherosclerosis by a high-fat diet, making them suitable for studying cardiovascular diseases and lipid metabolism.
There is considerable variation between different sublines of CBA/CaH mice, and care must be taken when comparing data from different sublines.
CBA/CaH mice also exhibit a high rate of spontaneous mutations, which may impact experimental outcomes and require careful genetic monitoring.
Originally developed by Strong (1920) from Bagg albino x DBA. Offspring split into a low mammary tumour incidence strain (CBA) and a high incidence strain (C3H). Strong to Andervont in 1947. Andervont to The Jackson Laboratory in 1948.Circa 1953 to the MRC Mammalian Genetics Unit, Harwell, hence the H in the nomenclature.
Received at ARC from CULAS (1997).
Received at Ozgene ARC from ARC (2023).
CBA/CaH strain is widely distributed and commonly used as a general-purpose strain in research due to its ease of handling and availability.
This strain of mice is a valuable research tool for studying cancer, cardiovascular diseases, and other areas of biomedical research.
Mouse images are representative only. Actual phenotypes may vary based on genotype, sex, age, husbandry, health status, and other factors.